Lea Hiršl

Lea Hiršl

Auto-generated profile, based on publicly available information

Lea Hiršl

Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
IBIlija Brizić
Ilija Brizić
BŠBožo Šušak
Božo Šušak
MAMaja Arapović
Maja Arapović
PHPeter C. Huszthy
Peter C. Huszthy
LHLea Hiršl
Lea Hiršl
SJStipan Jonjić
Stipan Jonjić

1 October 2018 in Microbes and Infection
Verified
Journal Article
Closed access
IBIlija Brizić
Ilija Brizić
LHLea Hiršl
Lea Hiršl
WBWilliam J. Britt
William J. Britt
AKAstrid Krmpotić
Astrid Krmpotić
SJStipan Jonjić
Stipan Jonjić

7 May 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LHLea Hiršl
Lea Hiršl
IBIlija Brizić
Ilija Brizić
TRTina Ružić
Tina Ružić
Vanda Juranic LisnicVanda Juranic Lisnic
Vanda Juranic Lisnic
JRJohanna Julia Reichel
Johanna Julia Reichel
SJStipan Jonjić
Stipan Jonjić
The development of a vaccine against human cytomegalovirus (CMV) has been a subject of long-term medical interest. The research during recent years identified CMV as an attractive vaccine vector against infectious diseases and tumors. The immune response to CMV persists over a lifetime and its unique feature is the inflationary T cell response to certain viral epitopes. CMV encodes numerous genes involved in immunoevasion, which are non-essential for virus growth in vitro. The deletion of those genes results in virus attenuation in vivo, which enables us to dramatically manipulate its virulence and the immune response. We have previously shown that the murine CMV (MCMV) expressing RAE-1γ, one of the cellular ligands for the NKG2D receptor, is highly attenuated in vivo but retains the ability to induce a strong CD8+ T cell response. Here, we demonstrate that recombinant MCMV expressing high affinity NKG2D ligand murine UL16 binding protein-like transcript (MULT-1) (MULT-1MCMV) inserted in the place of its viral inhibitor is dramatically attenuated in vivo in a NK cell-dependent manner, both in immunocompetent adult mice and in immunologically immature newborns. MULT-1MCMV was more attenuated than the recombinant virus expressing RAE-1γ. Despite the drastic sensitivity to innate immune control, MULT-1MCMV induced an efficient CD8+ T cell response to viral and vectored antigens. By using in vitro assay, we showed that similar to RAE-1γMCMV, MULT-1 expressing virus provided strong priming of CD8+ T cells. Moreover, MULT-1MCMV was able to induce anti-viral antibodies, which after passing the transplacental barrier protect offspring of immunized mothers from challenge infection. Altogether, this study further supports the concept that CMV expressing NKG2D ligand possesses excellent characteristics to serve as a vaccine or vaccine vector.